Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lantern Pharma Inc.'s SEC filings document a clinical-stage oncology company built around AI-enabled drug development, its RADR platform and related research technologies. The filings include Form 8-K reports for financial results, Regulation FD presentations, and demonstrations of withZeta.ai, including platform capabilities, commercial architecture, rare-cancer research applications and revenue strategy disclosures.
Proxy and annual-meeting filings cover board elections, equity incentive plan matters, option repricing, independent auditor ratification and stockholder voting results. The filing record also includes exhibit-based press releases and presentations, Inline XBRL cover data, and forward-looking-statement risk language tied to Lantern Pharma's clinical programs, AI platforms, capital needs and development-stage biotechnology operations.
Lantern Pharma Inc. director Maria-Luisa Maccecchini reported receiving two stock option grants. On January 9, 2026, she was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share, with the option priced at $0.00 on the grant date. She also received a second stock option for 21,152 shares at the same $3.49 exercise price.
Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The 25,000-share option vests in equal monthly installments over 24 months starting February 9, 2026, while the 21,152-share option vests in equal monthly installments over 12 months beginning on the same date. Following these grants, she directly beneficially owns 25,000 and 21,152 derivative securities, respectively.
Lantern Pharma Inc. director Chandru Vijay reported receiving two new stock option grants. On January 9, 2026, he was granted stock options to buy 25,000 shares of common stock at an exercise price of $3.49 per share under the company’s Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received stock options to buy an additional 17,307 shares of common stock at an exercise price of $3.49 per share under the same plan. This second grant vests in equal monthly installments over 12 months beginning February 9, 2026. Both grants are reported as directly owned derivative securities.
Lantern Pharma director Lee Troy Schalop reported new equity awards on a Form 4. On January 9, 2026, he received two grants of stock options (rights to buy common stock) with an exercise price of $3.49 per share. One grant covers 25,000 options that vest in equal monthly installments over 24 months starting February 9, 2026. The second grant covers 18,460 options that vest in equal monthly installments over 12 months starting the same date. Both awards were reported at a transaction price of $0.00 per option, reflecting that these are option grants rather than open-market purchases or sales.
Lantern Pharma Inc. director David S. Silberstein reported receiving two grants of stock options to buy the company’s common stock. On January 9, 2026, he was awarded 25,000 stock options with an exercise price of $3.49 per share under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received an additional 17,307 stock options with the same $3.49 exercise price under the same plan. This second grant vests in equal monthly installments over 12 months beginning on February 9, 2026. Both grants are held directly by Silberstein and represent compensation in the form of equity incentives rather than an open‑market purchase.
Lantern Pharma (LTRN) reported administrative updates via Form 8-K related to third-quarter communications. The company will release financial results for the quarter ended September 30, 2025 and host a conference call and live webinar on November 13, 2025. A press release is furnished as Exhibit 99.1 and an investor presentation as Exhibit 99.2. These materials are furnished, not filed, under the Exchange Act, so they are not subject to Section 18 liability or automatically incorporated into other filings.
Lantern Pharma (LTRN) filed its Q3 2025 10‑Q, reporting a net loss of $4,177,423 for the quarter and $13,045,221 for the nine months ended September 30, 2025. Operating expenses fell year over year as research and development declined to $2,436,971 in Q3 (from $3,716,646), while general and administrative rose to $1,912,829. Interest income was $100,921 and other income, net was $71,456.
Cash and cash equivalents were $8,389,486 and marketable securities were $3,973,090 at September 30, 2025. Working capital was approximately $9,421,000. Management states that existing cash, cash equivalents, and marketable securities are expected to fund operations until approximately late June 2026 to mid August 2026, and the filing raises “substantial doubt” about the company’s ability to continue as a going concern without substantial additional funding.
To bolster liquidity, Lantern entered an at‑the‑market program of up to $15,530,000. In Q3, it sold 212,444 shares for gross proceeds of $989,061 and paid $29,672 in commissions; from October 1 to the report date, it sold an additional 144,204 shares for gross proceeds of $634,333, with $19,030 in commissions.
Lantern Pharma Inc. filed a Form 8-K reporting voting tallies for one or more matters. The record shows totals including 5,189,274 votes and several vote-category counts such as 2,212,199, 2,214,833, 2,213,670, 2,213,088, and smaller counts listed as Against 758,870, Against 43,732, and Abstain 29,603 and 26,426. The filing names Lantern Pharma Inc. as a Delaware corporation and is signed by David R. Margrave, Chief Financial Officer.
Lantern Pharma (LTRN) director Vijay Chandru amended two outstanding stock options on 09/19/2025, replacing earlier awards with new options priced at $5.04 per share. The original options were granted on 06/15/2020 (9,135 underlying shares, originally $15 exercise price, expiration 06/14/2030) and 11/04/2021 (3,200 underlying shares, originally $10.32 exercise price, expiration 11/03/2031). The amendments cancelled the old options and granted replacement options covering the same share amounts, leaving Mr. Chandru with options for a total of 12,335 underlying shares exercisable under the stated expirations.
Panna Sharma, President & CEO and a director of Lantern Pharma Inc. (LTRN), amended an outstanding stock option originally granted on 06/15/2020. The amendment, recorded with a transaction date of 09/19/2025, canceled the prior option with a $15 exercise price covering 76,628 underlying shares and replaced it with a new option covering the same 76,628 shares at a reduced exercise price of $5.04. The option retains its original exercisability and expiration schedule (vested schedule described in the filing) and the replacement option shows 76,628 shares beneficially owned following the amendment. The form is signed by Ms. Sharma on 09/22/2025.
Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), filed a Form 4 reporting amendments to previously granted stock options. The filing shows two option amendments: a June 15, 2020 option was cancelled and replaced with a $5.04 exercise-price option covering 52,200 shares exercisable through 06/14/2030; a October 29, 2021 option was cancelled and replaced with a $5.04 exercise-price option covering 17,400 shares exercisable through 10/28/2031. After the replacements, Mr. Bhatia beneficially owns 52,200 and 17,400 underlying common shares for the respective options.